Brainstorm Cell Therapeutics Inc. (BCLI)
BCLI Stock Price Chart
Explore Brainstorm Cell Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze BCLI price movements and trends.
BCLI Company Profile
Discover essential business fundamentals and corporate details for Brainstorm Cell Therapeutics Inc. (BCLI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Oct 2003
Employees
27.00
Website
https://www.brainstorm-cell.comCEO
Chaim Lebovits
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
BCLI Financial Timeline
Browse a chronological timeline of Brainstorm Cell Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.35.
Earnings released on 14 Aug 2025
EPS came in at -$0.34 surpassing the estimated -$0.41 by +17.07%.
Earnings released on 15 May 2025
EPS came in at -$0.45 surpassing the estimated -$0.97 by +53.61%.
Earnings released on 31 Mar 2025
EPS came in at -$0.51 falling short of the estimated -$0.49 by -4.08%, while revenue for the quarter reached $849.00K .
Earnings released on 14 Nov 2024
EPS came in at -$1.80 falling short of the estimated -$0.45 by -300.00%.
Stock split effective on 1 Oct 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2024
EPS came in at -$0.60 matching the estimated -$0.60.
Earnings released on 14 May 2024
EPS came in at -$0.75 surpassing the estimated -$1.05 by +28.57%.
Earnings released on 1 Apr 2024
EPS came in at -$1.65 surpassing the estimated -$2.25 by +26.67%, while revenue for the quarter reached $343.00K .
Earnings released on 14 Nov 2023
EPS came in at -$2.10 matching the estimated -$2.10.
Earnings released on 14 Aug 2023
EPS came in at -$1.95 surpassing the estimated -$2.25 by +13.33%.
Earnings released on 15 May 2023
EPS came in at -$2.10 surpassing the estimated -$2.40 by +12.50%.
Earnings released on 30 Mar 2023
EPS came in at -$2.10 surpassing the estimated -$2.70 by +22.22%.
Earnings released on 14 Nov 2022
EPS came in at -$2.85 falling short of the estimated -$2.25 by -26.67%.
Earnings released on 15 Aug 2022
EPS came in at -$2.85 falling short of the estimated -$2.25 by -26.67%.
Earnings released on 16 May 2022
EPS came in at -$2.25 falling short of the estimated -$1.95 by -15.38%.
Earnings released on 28 Mar 2022
EPS came in at -$2.55 surpassing the estimated -$3.00 by +15.00%.
Earnings released on 15 Nov 2021
EPS came in at -$2.25 surpassing the estimated -$3.15 by +28.57%.
Earnings released on 5 Aug 2021
EPS came in at -$2.55 surpassing the estimated -$3.00 by +15.00%.
Earnings released on 26 Apr 2021
EPS came in at -$2.85 surpassing the estimated -$4.05 by +29.63%.
Earnings released on 4 Feb 2021
EPS came in at -$5.55 surpassing the estimated -$7.20 by +22.92%.
Earnings released on 15 Oct 2020
EPS came in at -$2.10 surpassing the estimated -$3.60 by +41.67%.
BCLI Stock Performance
Access detailed BCLI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.